AstraZeneca PLC announced that President of Research and Development, held by Martin Mackay, and Executive Vice President, Global Commercial, held by Tony Zook - have been eliminated. Martin Mackay and Tony Zook will leave the company at the end of January.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,260 GBX | +1.32% |
|
+1.69% | +15.66% |
Jul. 12 | Instil Bio Shares Surge Following Rental Agreement with AstraZeneca | DJ |
Jul. 12 | Sector Update: Health Care Stocks Mixed Premarket Friday | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.66% | 247B | |
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+4.21% | 230B | |
+17.90% | 228B | |
+14.86% | 177B | |
+0.45% | 164B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca PLC Announces Executive Changes